PF-07985045 + sasanlimab

PF-07985045 + sasanlimab is a combination investigational therapy currently in clinical trials for advanced solid tumors, including colorectal cancer and KRAS mutation-related tumors. PF-07985045 is a small molecule inhibitor targeting KRAS, specifically designed to block the oncogenic signaling of mutant KRAS proteins, which drive cancer progression[2][3]. Sasanlimab is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to programmed cell death protein 1 (PD-1), inhibiting its interaction with PD-L1 and PD-L2, thereby releasing inhibitory checkpoints on T cells and enhancing anti-tumor immunity[1][5]. This combination aims to attack tumors through dual mechanisms: direct inhibition of KRAS-driven cell proliferation and immune activation via checkpoint blockade. Both drugs are developed by Pfizer, which also sponsors ongoing early-phase and pivotal clinical trials in solid malignancies[1][2][3].